{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:33Z","timestamp":1753891833547,"version":"3.41.2"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH T32 AI07425-23, NIH T32 AI70478-01"],"award-info":[{"award-number":["NIH T32 AI07425-23, NIH T32 AI70478-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD19<jats:sup>+<\/jats:sup> CD5<jats:sup>+<\/jats:sup> clonal B lymphocytes in the blood, bone marrow, and peripheral lymphoid organs. Treatment options for patients range from historical chemoimmunotherapy (CIT) to small molecule inhibitors targeting pro-survival pathways in leukemic B cells, such as the Bruton\u2019s tyrosine kinase inhibitor ibrutinib (IBR). Using biobanked blood samples obtained pre-therapy and at standard response evaluation timepoints, we performed an in-depth evaluation of the blood innate and adaptive immune compartments between pentostatin-based CIT and IBR and looked for correlations with clinical sequelae. CD4<jats:sup>+<\/jats:sup> conventional T cells and CD8<jats:sup>+<\/jats:sup> cytotoxic T cells responded similarly to CIT and IBR, although exhaustion status differed. Both treatments dramatically increased the prevalence and functional status of monocyte, dendritic cell, and natural killer cell subsets. As expected, both regimens reduced clonal B cell levels however, we observed no substantial recovery of normal B cells. Although improvements in most immune subsets were observed with CIT and IBR at response evaluation, both patient groups remained susceptible to infections and secondary malignancies during the study.<\/jats:p>","DOI":"10.3389\/fonc.2023.1302038","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T05:16:45Z","timestamp":1701667005000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib"],"prefix":"10.3389","volume":"13","author":[{"given":"Baustin M.","family":"Welch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce A.","family":"Manso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Gwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra K.","family":"Lothert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay L.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2012.070","article-title":"Infectious complications in chronic lymphocytic leukemia","volume":"4","author":"Nosari","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000336","article-title":"Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG)","volume":"4","author":"Kutsch","year":"2020","journal-title":"Hemasphere"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1442716","article-title":"Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia","volume":"11","author":"Kay","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100930","DOI":"10.1016\/j.blre.2022.100930","article-title":"CLL update 2022: A continuing evolution in care","volume":"131","author":"Kay","year":"2022","journal-title":"Blood Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.51","article-title":"Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase","volume":"10","author":"Davids","year":"2014","journal-title":"Future Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40364-020-00253-w","article-title":"Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse","volume":"8","author":"Cadot","year":"2020","journal-title":"biomark Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.727531","article-title":"Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets \u2013 beyond B lymphocytes","volume":"9","author":"Zhu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.737943","article-title":"Clinical trials of the BTK inhibitors ibrutinib and acalabrutinib in human diseases beyond B cell Malignancies","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.250","article-title":"Quality assurance for polychromatic flow cytometry","volume":"1","author":"Perfetto","year":"2006","journal-title":"Nat Protoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2012.126","article-title":"Quality assurance for polychromatic flow cytometry using a suite of calibration beads","volume":"7","author":"Perfetto","year":"2012","journal-title":"Nat Protoc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.xpro.2021.100485","article-title":"Standardized flow-cytometry-based protocol to simultaneously measure transcription factor levels","volume":"2","author":"Manso","year":"2021","journal-title":"STAR Protoc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0280-0","article-title":"Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients","volume":"33","author":"Manso","year":"2019","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.1.163","article-title":"The role of the CD19\/CD21 complex in B cell processing and presentation of complement-tagged antigens","volume":"167","author":"Cherukuri","year":"2001","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2011.00081","article-title":"The relationship between CD27 negative and positive B cell populations in human peripheral blood","volume":"2","author":"Wu","year":"2011","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.04.016","article-title":"Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70","volume":"39","author":"Lafarge","year":"2015","journal-title":"Leukemia Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1403598","article-title":"Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment","volume":"59","author":"Shen","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41467-019-14081-6","article-title":"Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL","volume":"11","author":"Rendeiro","year":"2020","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"106520","DOI":"10.1016\/j.leukres.2021.106520","article-title":"Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia","volume":"102","author":"Solman","year":"2021","journal-title":"Leuk Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610659","article-title":"Revealing a phenotypical appearance of ibrutinib resistance in patients with chronic lymphocytic leukaemia by flow cytometry","volume":"28","author":"Tak\u00e1cs","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115717","article-title":"CD23 antigen regulation and signaling in chronic lymphocytic leukemia","volume":"89","author":"Fournier","year":"1992","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"25629","DOI":"10.1038\/srep25629","article-title":"CD23 can negatively regulate B-cell receptor signaling","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2016.00146","article-title":"CD24: A rheostat that modulates cell surface receptor signaling of diverse receptors","volume":"4","author":"Ayre","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1203652","article-title":"Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination","volume":"76","author":"L\u00f3pez-Giral","year":"2004","journal-title":"J Leukocyte Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"De Rooij","year":"2012","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554220","article-title":"Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib","volume":"123","author":"Wodarz","year":"2014","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021342118","article-title":"CD20 as a gatekeeper of the resting state of human B cells","volume":"118","author":"Kl\u00e4sener","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-709519","article-title":"Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis","volume":"128","author":"Pavlasova","year":"2016","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients","volume":"139","author":"Shanafelt","year":"2007","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171288","article-title":"Functional and clinical relevance of VLA-4 (CD49d\/CD29) in ibrutinib-treated chronic lymphocytic leukemia","volume":"215","author":"Tissino","year":"2018","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.03.010","article-title":"Can immunocompetence be restored in chronic lymphocytic leukemia","volume":"35","author":"Sun","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02832","article-title":"Long-term ibrutinib therapy reverses CD8(+) T cell exhaustion in B cell chronic lymphocytic leukaemia","volume":"10","author":"Parry","year":"2019","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence","volume":"19","author":"Davis","year":"2021","journal-title":"J Transl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055805","article-title":"Identification and classification of distinct surface markers of T regulatory cells","volume":"13","author":"Wegrzyn","year":"2023","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020554","article-title":"Ibrutinib-based therapy reinvigorates CD8 T cells compared to chemoimmunotherapy: immune-monitoring from the E1912 trial","author":"Papazoglou","year":"2023","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608024","article-title":"Beyond T-cells: functional characterization of CTLA-4 expression in immune and non-immune cell types","volume":"11","author":"Oyewole-Said","year":"2020","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000203709","article-title":"Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha","volume":"96","author":"Katrinakis","year":"1996","journal-title":"Acta Haematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"Macfarlane","year":"2017","journal-title":"Oncoimmunology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136665","article-title":"NK cells in chronic lymphocytic leukemia and their therapeutic implications","volume":"22","author":"Sportoletti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.005","article-title":"Location and cellular stages of natural killer cell development","volume":"34","author":"Yu","year":"2013","journal-title":"Trends Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx224","article-title":"CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET\/CT in patients at risk for cardiovascular disease","volume":"114","author":"Verweij","year":"2018","journal-title":"Cardiovasc Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.771210","article-title":"Targeting the CCL2\/CCR2 axis in cancer immunotherapy: one stone, three birds","volume":"12","author":"Fei","year":"2021","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01593","article-title":"CD38 is robustly induced in human macrophages and monocytes in inflammatory conditions","volume":"9","author":"Amici","year":"2018","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183594","article-title":"The MHC class II antigen presentation pathway in human monocytes differs by subset and is regulated by cytokines","volume":"12","author":"Lee","year":"2017","journal-title":"PloS One"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.105","article-title":"Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia","volume":"28","author":"Saulep-Easton","year":"2014","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.292","article-title":"Salvage therapy for CLL and the role of stem cell transplantation","volume":"2005","author":"Gribben","year":"2005","journal-title":"Hematology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24282","article-title":"Chronic lymphocytic leukemia (CLL)-Then and now","volume":"91","author":"Rai","year":"2016","journal-title":"Am J Hematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1697226","article-title":"Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia","volume":"13","author":"Khan","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bjh.18014","article-title":"COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity","volume":"197","author":"Shen","year":"2022","journal-title":"Br J Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.992137","article-title":"B-cell Malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)","volume":"12","author":"Infante","year":"2022","journal-title":"Front Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.10.2146","article-title":"Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia","volume":"12","author":"Reinisch","year":"1994","journal-title":"J Clin Oncol"},{"key":"B68","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062376","article-title":"Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia","volume":"14","author":"Noto","year":"2023","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1371399","article-title":"TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia","volume":"7","author":"Catakovic","year":"2017","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-476606","article-title":"Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity","volume":"121","author":"Reiners","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1302038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T05:16:48Z","timestamp":1701667008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1302038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":73,"alternative-id":["10.3389\/fonc.2023.1302038"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1302038","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"article-number":"1302038"}}